Home
Leadership
Policy Areas
Resources
Reports
05.11.23
RDCC Proposes Policy Solutions to Remove Barriers for Rare Disease Patients Seeking Treatment Options and Increase Equity of Access
Read more
Resources
03.22.23
RDCC Urges Congress to Reject Proposals that Undermine the Intent of Accelerated Approval for Rare Disease Patients
Read more
Resources
03.14.23
RDCC Sends Letter of Support for Four Rare Disease Bills to Minnesota State Legislators and Expresses Concern for Fifth Bill that Threatens Drug Development
Read more
Resources
01.09.23
Learn more about how the Orphan Drug Act enables researchers to discover breakthrough cures for rare diseases
Read more
Resources
12.06.22
RDCC Submits Comments on Equal Employment Opportunity Commission’s FY 2022-2026 Draft Strategic Plan
Read more
Resources
12.06.22
Join RDCC in Support of “Leo’s Law”
Read more
Resources
11.03.22
Arbitrary Price Controls have a Negative, Disproportionate Impact on Rare Disease Treatment Development
Read more
Resources
09.15.22
RDCC Urges Swift Action to Reauthorize PDUFA in Letter to Congressional Leaders
Read more
Resources
09.01.22
Understanding and Modernizing Newborn Screening
Read more
Resources
08.24.22
Comments Submitted to Colorado PDAB on Draft Proposed Rule Concerning the Affordability Review of Prescription Drugs
Read more
Resources
06.06.22
A Patient-Centric Approach to Evaluate Rare Disease Treatments
Read more
Resources
05.16.22
The Orphan Drug Tax Credit is a Proven Catalyst for Investment and Treatment Development
Read more
Resources
04.28.22
RDCC Supports Policy Proposals That Recognize the Potential of Rare Disease Therapies and Reinforce the Role of the Accelerated Approval Pathway
Read more
Resources
04.14.22
The Rare Disease Company Coalition Expresses Concern to CMS on Oregon’s Application for a Section 1115 Demonstration Waiver
Read more
Resources
03.30.22
RDCC Offers Endorsement of the Bipartisan BENEFIT Act in Support of Patient Engagement in Drug Development
Read more
Resources
02.24.22
Our Policy Focus Areas
Read more
Resources
01.14.22
The Rare Disease Company Coalition Submits Comments on Oregon’s Application for a Section 1115 Demonstration Waiver
Read more
Resources
10.20.21
Video: The Challenges of “One-Size-Fits-All” Approaches to Healthcare Policy Reform
Read more
Resources
09.17.21
Existing Value Frameworks to Negotiate Pricing for Rare Disease Drugs Disproportionately Impacts People Suffering from Rare Diseases
Read more